



BN/SB/08A/B

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of 3

Complete if Known

| | |
|------------------------|---------------|
| Application Number | 10/540,852 |
| Filing Date | June 27, 2005 |
| First Named Inventor | Kenji OKAJIMA |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | OKAJIMA |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| | | Number-Kind Code ² (if known) | | | |
| | AA | US-4,775,624 | 10-04-1988 | Bang et al | |
| | AB | US-5,147,838 | 09-15-1992 | Esmon et al | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|-----------------------|--------------------------|---|--------------------------------|--|---|----------------|
| | | Country Code ³ Number ⁴ Kind Code ⁵ (if known) | | | | |
| | AC | JP 61-205487 | 09-11-1986 | Eli Lilly and Company | | |
| | AD | EP 0 266 190 A2 | 05-04-1988 | ZymoGenetics Inc. | | |
| | AE | JP 64-85084 | 03-30-1989 | ZymoGenetics Inc. | | |
| | AF | WO 95/34319 A1 | 12-21-1995 | Genentech, Inc. | | |
| | AG | JP 10-501813 | 02-17-1998 | Genentech, Inc. | | |


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|-----------------------|--------------------------|--|----------------|
| | | | |
| | AH | AOKI et al, "A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation", <u>Int J Hematol</u> 75(5):540-547 (2002) | |
| | AI | BAJZAR et al, "The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent", <u>Blood</u> 88(6):2093-2100 (1996) | |
| | AJ | BERNARD et al, "Efficacy and safety of recombinant human activated protein C for severe sepsis", <u>N Engl J Med</u> 344(10):699-709 (2001) | |

Examiner
SignatureDate
Considered

11-28-06

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



BN/SB/08A/B

| | | | |
|--|---|--------------------------|---|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| Application Number | | 10/540,852 | |
| Filing Date | | June 27, 2005 | |
| First Named Inventor | | Kenji OKAJIMA | |
| Group Art Unit | | | |
| Examiner Name | | | |
| Sheet | 2 | of | 3 |
| Attorney Docket Number | | OKAJIMA1 | |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| | AK | COMP et al, "Determination of functional levels of protein C, an antithrombotic protein, using thrombin-thrombomodulin complex", <u>Blood</u> 63(1):15-21 (1984) | |
| | AL | GLASSMAN et al, "Thrombosis and coagulation abnormalities associated with cancer", <u>Ann Clin Lab Sci</u> 24(1):1-5 (1994) | |
| | AM | HALKIN et al, "Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis", <u>Ann InternMed</u> 96(5):561-565 (1982) | |
| | AN | IKEDA Y, "Atarashii Kokessen 'yaku Kakuron' Kogyokoyaku (2) Kasseika Protein C", <u>Iyaku Journal</u> 35(4):1061-1066 (1999) | |
| | AO | JOYCE et al, "Disseminated Intravascular Coagulation in Severe Sepsis Patients Treated with Recombinant Human Activated Protein C, a Retrospective Subgroup Analysis from the PROWESS Trial", <u>Blood</u> 98(11):445a, 43 rd Annual Meeting Program Abstracts, #1866 (2001) | |
| | AP | KATSUURA Y, "Kokessen 'yaku no Genjo to Shin 'yaku Kaihatsu Kasseika Protein C no Kokessen Sayo", <u>Folia Pharmacologica Japonica</u> 116(5):290-297 (2000) | |
| | AQ | KINGSTON et al, "Peri-operative heparin: a possible adjuvant to surgery in colo-rectal cancer", <u>Int J Colorect Dis</u> 8(2):111-115 (1993) | |
| | AR | KISIEL et al, "Anticoagulant properties of bovine plasma protein C following activation by thrombin", <u>Biochemistry</u> 16(26):5824-5831 (1977) | |
| | AS | KISIEL W, "Human plasma protein C: isolation, characterization, and mechanism of activation by alpha-thrombin", <u>J Clin Invest</u> 64(3):761-769 (1979) | |
| | AT | KOHANNA et al, "Effect of perioperative low-dose heparin administration on the course of colon cancer", <u>Surgery</u> 93(3):433-438 (1983) | |
| AU | LACAPRA et al, "The use of thrombus precursor protein, D-dimer, prothrombin fragment 1.2, and thrombin antithrombin in the exclusion of proximal deep vein thrombosis and pulmonary embolism", <u>Blood Coagul Fibrinolysis</u> 11(4):371-377 (2000) | | |
| AV | LEBEAU et al, "Subcutaneous heparin treatment increases survival in small cell lung cancer", <u>Cancer</u> 74(1):38-45 (1994) | | |

| | | | |
|--------------------|--|-----------------|----------|
| Examiner Signature | | Date Considered | 11/28/06 |
|--------------------|--|-----------------|----------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



BN/SB/08A/B

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3

of 3

Complete if Known

| | |
|------------------------|---------------|
| Application Number | 10/540,852 |
| Filing Date | June 27, 2005 |
| First Named Inventor | Kenji OKAJIMA |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | OKAJIMA1 |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|--------------------|---|---|----------------|
| 64 | AW | LORETO et al, "Coagulation and cancer: implications for diagnosis and management", <u>Patho Oncol Res</u> 6(4):301-312 (2000) | |
| | AX | MITATE et al, "Kessensho no Rinsho-Ekigaku to Byotai DIC-Byotai no Tayosei", <u>Medicina</u> 37(5):735-737 (2000) | |
| | AY | MURAKAMI et al, "Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production", <u>Am J Physiol</u> 272(2 Pt 1):L197-L202 (1997) | |
| | AZ | REZAI A, "Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C", <u>J Biol Chem</u> 276(19):15567-15570 (2001) | |
| | BA | SAKATA et al, "Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity", <u>Proc Natl Acad Sci USA</u> 82(4):1121-1125 (1985) | |
| | BB | SCATES S, "Diagnosis and treatment of cancer-related thrombosis", <u>Semin Thromb Hemost</u> 18(4):373-379 (1992) | |
| | BC | SUTHERLAND et al, "Thromboembolic complications of cancer: epdemiology, pathogenesis, diagnosis, and treatment", <u>Am J Hematol</u> 72(1):43-52 (2003) | |
| | BD | SUZUKI et al, "Inactivation of human coagulation factor V by activated protein C", <u>J Biol Chem</u> 258(3):1914-1920 (1983) | |
| | BE | TAYLOR et al, "Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon", <u>J Clin Invest</u> 79(3):918-925 (1987) | |
| | BF | ZACHARSKI L, "Basis for selection of anticoagulant drugs for therapeutic trials in human malignancy", <u>Haemostasis</u> 16:(3-4):300-320 (1986) | |
| BG | ZACHARSKI L, "Heparin and cancer", <u>Thromb Haemost</u> 80(1):10-23 (1998) | | |
| BH | The Welfare Ministry, Research team for specified diseases, coagulopathy, Report in 1987 p.37-41 (1988) | | |

Examiner
SignatureDate
Considered

11-28-06

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.